Who are Previscan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Indion, Oraflex, Andion, Caricide, Ascaricid, Feximac.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluindione.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Previscan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Previscan (FLUINDIONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: fluindione. Area: Gastroenterology.

phase 2 fluindione Arachidonate 5-lipoxygenase Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Previscan (FLUINDIONE). Previscan works by inhibiting vitamin K-dependent clotting factors in the liver.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Previscan TARGET	FLUINDIONE		phase 2	fluindione	Arachidonate 5-lipoxygenase
Indion	PHENINDIONE	Sanofi	marketed	phenindione	Prothrombin, Vitamin K epoxide reductase complex subunit 1, Arachidonate 5-lipoxygenase	1982-01-01
Oraflex	BENOXAPROFEN		marketed	benoxaprofen	Arachidonate 5-lipoxygenase	1982-01-01
Andion	ANISINDIONE	Merck & Co.	marketed	anisindione	Vitamin K-dependent gamma-carboxylase, Arachidonate 5-lipoxygenase	1957-01-01
Caricide	DIETHYLCARBAMAZINE	Pfizer	marketed	Anthelmintic	Arachidonate 5-lipoxygenase	1950-01-01
Ascaricid	hexylresorcinol		marketed	hexylresorcinol	Arachidonate 5-lipoxygenase, Tyrosinase, Polyphenol oxidase 2
Feximac	BUFEXAMAC		marketed	bufexamac	Histone deacetylase 10, Histone deacetylase 6, Arachidonate 5-lipoxygenase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (fluindione class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Previscan — Competitive Intelligence Brief. https://druglandscape.com/ci/fluindione. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing